Document Format Files
Seq | Description | Document | Type | Size |
---|---|---|---|---|
1 | REGISTRATION STATEMENT | ea0205122-01.htm iXBRL | S-4 | 11187490 |
2 | AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF ORUKA THERAPEUTICS, INC | ea020512201ex3-5_arcabio.htm | EX-3.5 | 129870 |
3 | BYLAWS OF ORUKA THERAPEUTICS, INC, AS CURRENTLY IN EFFECT | ea020512201ex3-6_arcabio.htm | EX-3.6 | 102170 |
4 | INVESTOR RIGHTS AGREEMENT, DATED MARCH 6, 2024, BY AND AMONG ORUKA THERAPEUTICS, | ea020512201ex4-3_arcabio.htm | EX-4.3 | 146682 |
5 | ORUKA THERAPEUTICS, INC. 2024 EQUITY INCENTIVE PLAN | ea020512201ex10-40_arcabio.htm | EX-10.40 | 95535 |
6 | FORM OF RESTRICTED STOCK NOTICE AND RESTRICTED STOCK PURCHASE AGREEMENT OF ORUKA | ea020512201ex10-41_arcabio.htm | EX-10.41 | 90208 |
7 | FORM OF STOCK OPTION AGREEMENT UNDER ORUKA THERAPEUTICS, INC. 2024 EQUITY INCENT | ea020512201ex10-42_arcabio.htm | EX-10.42 | 80436 |
8 | AMENDED AND RESTATED DIRECTOR OFFER LETTER, DATED MARCH 22, 2024, BETWEEN ORUKA | ea020512201ex10-43_arcabio.htm | EX-10.43 | 15782 |
9 | DIRECTOR OFFER LETTER, DATED APRIL 24, 2024, BETWEEN ORUKA THERAPEUTICS, INC. AN | ea020512201ex10-44_arcabio.htm | EX-10.44 | 10924 |
10 | FORM OF INDEMNIFICATION AGREEMENT BETWEEN ORUKA THERAPEUTICS, INC. AND ITS DIREC | ea020512201ex10-45_arcabio.htm | EX-10.45 | 81171 |
11 | AMENDED AND RESTATED EMPLOYMENT OFFER LETTER, DATED FEBRUARY 14, 2024, BY AND BE | ea020512201ex10-46_arcabio.htm | EX-10.46 | 64750 |
12 | AMENDED AND RESTATED EMPLOYMENT OFFER LETTER, DATED MARCH 11, 2024, BY AND BETWE | ea020512201ex10-47_arcabio.htm | EX-10.47 | 69104 |
13 | AMENDED AND RESTATED EMPLOYMENT OFFER LETTER, DATED MARCH 15, 2024, BY AND BETWE | ea020512201ex10-48_arcabio.htm | EX-10.48 | 61203 |
14 | AMENDED AND RESTATED EMPLOYMENT OFFER LETTER, DATED APRIL 12, 2024, BY AND BETWE | ea020512201ex10-49_arcabio.htm | EX-10.49 | 54221 |
15 | LIST OF SUBSIDIARIES OF ARCA BIOPHARMA, INC | ea020512201ex21-1_arcabio.htm | EX-21.1 | 3733 |
16 | CONSENT OF KPMG LLP, INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM OF ARCA BIOPH | ea020512201ex23-1_arcabio.htm | EX-23.1 | 1774 |
17 | CONSENT OF PRICEWATERHOUSECOOPERS LLP, INDEPENDENT REGISTERED PUBLIC ACCOUNTING | ea020512201ex23-2_arcabio.htm | EX-23.2 | 1546 |
18 | CONSENT OF LUCID CAPITAL MARKETS, LLC | ea020512201ex99-5_arcabio.htm | EX-99.5 | 5234 |
19 | CONSENT OF LAWRENCE KLEIN TO SERVE AS A DIRECTOR OF ARCA BIOPHARMA, INC., TO BE | ea020512201ex99-6_arcabio.htm | EX-99.6 | 2452 |
20 | CONSENT OF KRISTINE BALL TO SERVE AS A DIRECTOR OF ARCA BIOPHARMA, INC., TO BE R | ea020512201ex99-7_arcabio.htm | EX-99.7 | 2435 |
21 | CONSENT OF CARL DAMBKOWSKI TO SERVE AS A DIRECTOR OF ARCA BIOPHARMA, INC., TO BE | ea020512201ex99-8_arcabio.htm | EX-99.8 | 2441 |
22 | CONSENT OF PETER HARWIN TO SERVE AS A DIRECTOR OF ARCA BIOPHARMA, INC., TO BE RE | ea020512201ex99-9_arcabio.htm | EX-99.9 | 2398 |
23 | CONSENT OF SAMARTH KULKARNI TO SERVE AS A DIRECTOR OF ARCA BIOPHARMA, INC., TO B | ea020512201ex99-10_arcabio.htm | EX-99.10 | 2406 |
24 | CONSENT OF CAMERON TURTLE TO SERVE AS A DIRECTOR OF ARCA BIOPHARMA, INC., TO BE | ea020512201ex99-11_arcabio.htm | EX-99.11 | 2400 |
25 | FILING FEE TABLE | ea020512201ex-fee_arcabio.htm | EX-FILING FEES | 22092 |
26 | GRAPHIC | tarca_001.jpg | GRAPHIC | 61255 |
27 | GRAPHIC | timage_001.jpg | GRAPHIC | 552437 |
28 | GRAPHIC | timage_002.jpg | GRAPHIC | 913184 |
29 | GRAPHIC | timage_003.jpg | GRAPHIC | 237818 |
30 | GRAPHIC | timage_004.jpg | GRAPHIC | 319835 |
31 | GRAPHIC | timage_005.jpg | GRAPHIC | 121237 |
32 | GRAPHIC | timage_006.jpg | GRAPHIC | 315435 |
33 | GRAPHIC | timage_007.jpg | GRAPHIC | 321935 |
34 | GRAPHIC | tlucid_sig.jpg | GRAPHIC | 29511 |
35 | GRAPHIC | toruka_logo.jpg | GRAPHIC | 97711 |
36 | GRAPHIC | ex10-43_001.jpg | GRAPHIC | 3410 |
37 | GRAPHIC | ex10-44_001.jpg | GRAPHIC | 3326 |
38 | GRAPHIC | ex10-48_001.jpg | GRAPHIC | 3017 |
39 | GRAPHIC | ex10-49_001.jpg | GRAPHIC | 3016 |
40 | GRAPHIC | ex23-1_001.jpg | GRAPHIC | 3683 |
Complete submission text file | 0001213900-24-042529.txt | 26983994 |
Data Files
Seq | Description | Document | Type | Size |
---|---|---|---|---|
41 | XBRL SCHEMA FILE | abio-20240331.xsd | EX-101.SCH | 46299 |
42 | XBRL CALCULATION FILE | abio-20240331_cal.xml | EX-101.CAL | 31860 |
43 | XBRL DEFINITION FILE | abio-20240331_def.xml | EX-101.DEF | 252559 |
44 | XBRL LABEL FILE | abio-20240331_lab.xml | EX-101.LAB | 455056 |
45 | XBRL PRESENTATION FILE | abio-20240331_pre.xml | EX-101.PRE | 261234 |
105 | EXTRACTED XBRL INSTANCE DOCUMENT | ea0205122-01_htm.xml | XML | 1617419 |
IRS No.: 363855489 | State of Incorp.: DE | Fiscal Year End: 1231
Type: S-4 | Act: 33 | File No.: 333-279387 | Film No.: 24941169
SIC: 2835 In Vitro & In Vivo Diagnostic Substances
(CF Office: 03 Life Sciences)